About GuideTX
GuideTX is a company based in Tucker (United States) founded in 2019 by James Dahlman was acquired by Beam Therapeutics in February 2021. GuideTX has raised $19.86 million across 4 funding rounds from investors including Beam Therapeutics, GreatPoint Ventures and Biomatics Capital. GuideTX operates in a competitive market with competitors including Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science, among others.
- Headquarter Tucker, United States
- Founders James Dahlman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$19.86 M (USD)
in 4 rounds
-
Latest Funding Round
$5.86 M (USD), Series A
Aug 11, 2020
-
Investors
Beam Therapeutics
& 2 more
-
Employee Count
Not available
-
Acquired by
Beam Therapeutics
(Feb 23, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of GuideTX
Unlock access to complete
Unlock access to complete
Funding Insights of GuideTX
GuideTX has successfully raised a total of $19.86M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.86 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GuideTX
GuideTX has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Beam Therapeutics, GreatPoint Ventures and Biomatics Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage tech and life sciences focused VC firm investing primarily in the US
|
Locked | Locked | Locked | |
|
Developer of gene therapy using CRISPR base editing to treat diseases
|
Locked | Locked | Locked |
Investor details for GuideTX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GuideTX
Investment portfolio details for GuideTX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GuideTX
Detailed financials for GuideTX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Guidetx Comparisons
Peer comparison for GuideTX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GuideTX
GuideTX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| Locked | Locked | Locked |
Lentivirus-based gene and cell therapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Oligonucleotide delivery systems are developed for targeted gene therapy.
|
Detailed competitors of GuideTX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Guidetx
Complete news archive for GuideTX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GuideTX
GuideTX was founded in 2019.
GuideTX is headquartered in Tucker, United States. It is registered at Tucker, Georgia, United States.
GuideTX is a funded company, having raised a total of $19.86M across 4 funding rounds to date.
Founded in 2019 and based in Tucker, United States, GuideTx operates in the biotechnology sector focused on nucleic acid therapeutics. Delivery systems for DNA and RNA are developed to treat diseases at the genetic level. A flagship lipid nanoparticle is offered for RNA transport to hepatocytes, with FDA approval achieved. A proprietary screening platform is utilized to create nanoparticles for functional delivery into cytoplasm or nucleus.
GuideTX's top competitors include Phase Genomics, Genenta Science and Genedit.
GuideTX has 3 investors. Key investors include Beam Therapeutics, GreatPoint Ventures, and Biomatics Capital.